Literature DB >> 19006617

Extraintestinal manifestations of inflammatory bowel disease.

Horace Williams1, David Walker, Timothy R Orchard.   

Abstract

The idiopathic inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, may be complicated by extraintestinal manifestations (EIMs) in up to 40% of patients. Reports suggest that almost every organ system may be affected. The EIMs are a significant cause of morbidity and may be particularly distressing for the patient. Recent attempts have been made to define the phenotype of IBD in patients of different ethnicities. These studies have highlighted potential racial variations in the prevalence of specific EIMs, findings that are perhaps not surprising given the influence of genetic factors in their pathogenesis. Certain EIMs are related to the activity of the bowel disease, and their management often involves careful monitoring while the IBD is brought under control. Other EIMs, however, typically run a course independent of the IBD activity, and specific, targeted treatments may be required, even including biologic agents such as infliximab.

Entities:  

Mesh:

Year:  2008        PMID: 19006617     DOI: 10.1007/s11894-008-0108-6

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  81 in total

1.  Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease.

Authors:  E J Lamb; T Wong; D J Smith; D E Simpson; A J Coakley; C Moniz; A F Muller
Journal:  Aliment Pharmacol Ther       Date:  2002-11       Impact factor: 8.171

Review 2.  Diagnosis and treatment of pyoderma gangrenosum.

Authors:  Trevor Brooklyn; Giles Dunnill; Chris Probert
Journal:  BMJ       Date:  2006-07-22

Review 3.  Skin manifestations of inflammatory bowel disease.

Authors:  Shereen Timani; Diya F Mutasim
Journal:  Clin Dermatol       Date:  2008 May-Jun       Impact factor: 3.541

Review 4.  Treatment of pyoderma gangrenosum.

Authors:  R K Chow; V C Ho
Journal:  J Am Acad Dermatol       Date:  1996-06       Impact factor: 11.527

Review 5.  Pyoderma gangrenosum.

Authors:  J P Callen
Journal:  Lancet       Date:  1998-02-21       Impact factor: 79.321

6.  A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease.

Authors:  Sandra Henderson; Neville Hoffman; Richard Prince
Journal:  Am J Gastroenterol       Date:  2006-01       Impact factor: 10.864

Review 7.  Probiotics in arthralgia and spondyloarthropathies in patients with inflammatory bowel disease. Prospective randomized trials are necessary.

Authors:  O Karimi; A S Peña
Journal:  Rev Esp Enferm Dig       Date:  2005-08       Impact factor: 2.086

8.  Sclerosing cholangitis.

Authors:  George R MacFaul; Roger W Chapman
Journal:  Curr Opin Gastroenterol       Date:  2004-05       Impact factor: 3.287

9.  The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects.

Authors:  H Mielants; E M Veys; M De Vos; C Cuvelier; S Goemaere; L De Clercq; L Schatteman; D Elewaut
Journal:  J Rheumatol       Date:  1995-12       Impact factor: 4.666

Review 10.  Basic and clinical aspects of osteoporosis in inflammatory bowel disease.

Authors:  Lorena Rodríguez-Bores; Josué Barahona-Garrido; Jesús K Yamamoto-Furusho
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

View more
  24 in total

1.  Biologic Therapies for Crohn's Disease: Update from the 2009 ACG Meeting.

Authors:  David G Binion
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-01

Review 2.  Management of arthropathy in inflammatory bowel diseases.

Authors:  Rosario Peluso; Francesco Manguso; Maria Vitiello; Salvatore Iervolino; Matteo Nicola Dario Di Minno
Journal:  Ther Adv Chronic Dis       Date:  2015-03       Impact factor: 5.091

3.  Hepatopancreatobiliary manifestations of inflammatory bowel disease.

Authors:  Kazuhiko Nakamura; Tetsuhide Ito; Kazuhiro Kotoh; Eikichi Ihara; Haruei Ogino; Tsutomu Iwasa; Yoshimasa Tanaka; Yoichiro Iboshi; Ryoichi Takayanagi
Journal:  Clin J Gastroenterol       Date:  2012-01-06

Review 4.  Pulmonary manifestations of inflammatory bowel disease.

Authors:  Xiao-Qing Ji; Li-Xia Wang; De-Gan Lu
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

5.  Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab.

Authors:  Ileana Duca; Patricia Ramírez de la Piscina; Silvia Estrada; Rosario Calderón; Katerina Spicakova; Leire Urtasun; Carlos Marra-López; Salvador Zabaleta; Raquel Bengoa; María Asunción Marcaide; Francisco García-Campos
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

Review 6.  Ulcerative Colitis: Update on Medical Management.

Authors:  Heba N Iskandar; Tanvi Dhere; Francis A Farraye
Journal:  Curr Gastroenterol Rep       Date:  2015-11

Review 7.  Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria.

Authors:  Angelo V Marzano; Rim S Ishak; Simone Saibeni; Carlo Crosti; Pier Luigi Meroni; Massimo Cugno
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

8.  Increased risk of periodontitis among patients with Crohn's disease: a population-based matched-cohort study.

Authors:  Ying-Chen Chi; Jiunn-Liang Chen; Li-Hsuan Wang; Koyin Chang; Chen-Long Wu; Shu-Yi Lin; Joseph Jordan Keller; Chyi-Huey Bai
Journal:  Int J Colorectal Dis       Date:  2018-07-12       Impact factor: 2.571

Review 9.  Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease.

Authors:  Guru Trikudanathan; Preethi G K Venkatesh; Udayakumar Navaneethan
Journal:  Drugs       Date:  2012-12-24       Impact factor: 9.546

Review 10.  Oral manifestation in inflammatory bowel disease: a review.

Authors:  Kamran B Lankarani; Gholam Reza Sivandzadeh; Shima Hassanpour
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.